AzTrials
AzTrials

Periodontal Disease "Unrecognized Condition"DPOGDNASNCT02523326

Design of a Protocol for Obtaining Genomic DNA From Saliva

An observational study of Periodontal Disease "Unrecognized Condition", run by Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás at 1 site in Mexico.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objective The aim of this study was to test a protocol for the extraction of high quality genomic DNA from saliva samples obtained with mouthwash and taken from patients with periodontal disease. Materials and methods Saliva samples were taken from 60 patients, then stored at room temperature. Read more about this study

Who is it for?
Ages 35 to 45 years
What is being tested?
saliva samples obtained with mouthwash
Type of treatment
Medical device
How many people
60 participants
Where
1 siteMexico
Study dates
Feb 2015to Sep 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: patients diagnosed with severe chronic periodontitis

Who may be able to join

  • patients diagnosed with severe chronic periodontitis
  • who signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA

Who cannot join

  • NO diagnosed with severe chronic periodontitis
  • NO signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA

Trial locations and contacts

1 site in 1 country.

Ángel Chávez Mendoza, PhD student contact

57296300 ext. 6280

angelchm77@hotmail.com

Mexico1 site, 1 recruiting
  • Angel Chavez Mendoza

    México, D.f., 11340

    Higinio Estrada Juárez, DOCTORATE, 55209900 ext. . 287, higinio.estrada@inper.mx

    Recruiting

Other trials in Mexico

About this study

Official title: Design of a Protocol for Obtaining Genomic DNA From Saliva Using Mouthwash: Samples Taken From Patients With Periodontal Disease

Objective The aim of this study was to test a protocol for the extraction of high quality genomic DNA from saliva samples obtained with mouthwash and taken from patients with periodontal disease.

Materials and methods Saliva samples were taken from 60 patients, then stored at room temperature. DNA extraction was carried out at distinct post-sampling times (10, 20 and 30 days). Evaluation of genomic DNA was performed with spectrophotometry, electrophoresis, and PCR genotyping and sequencing.

Read the detailed description

Materials and methods 2.1. Patients The study was conducted with 60 patients diagnosed with severe chronic periodontitis in the Periodontic Clinic of the Interdisciplinary Health Sciences Center (Santo Tomás Unit), National Polytechnic Institute. The protocol of this study was approved by the Research and Bioethics Committee of the School of Medicine. National Polytechnic Institute. Informed consent was obtained from all participants included in the study, who signed the appropriate form allowing for the collection of saliva samples and the extraction of genomic DNA. Ethical norms for research on human beings, established by the Declaration of Helsinki (1975; updated most recently in 2008) were strictly followed. Each patient was instructed how to prepare for saliva sampling, which involved brushing their teeth at least 2 h previously and abstaining from eating or drinking anything.

2.2. Taking the sample In a tube of 50 ml were placed 10 ml mouthwash (Listerine Cool Mint, Johnson \& Johnson, 21.6% alcohol). Patients were instructed to rinse their mouth vigorously with this quantity of mouthwash during 30 s, then spit it into the tube. Once collected, the samples were stored at room temperature (20°C - 24°C). The 60 samples were divided into 3 groups (n=20), and the extraction of DNA was performed at distinct times: group A at 10 days, group B at 20 days and group C at 30 days.

2.3. DNA extraction To separate the mouthwash, the tube was centrifuged during 10 min at 10750x g. The supernatant was poured out and the cellular pellet washed with 1 ml of PBS, resuspended in the vortex for 30 s, and transferred to a new 2 ml tube. It was then centrifuged for 5 min at 2000x g, the supernatant poured out, and the pellet washed with 1.5 ml of PBS and resuspended in the vortex for 30 s. To this solution was added a 1 ml solution of lysis of nucleated cells (Wizard® Genomic DNA Purification Kit) before being shaken for 20 s, followed by incubation at 37 °C for 10 min. After adding 300 µl of protein precipitator solution (Wizard® Genomic DNA Purification Kit), the mixture was placed on ice for 5 min and then centrifuged at 15000x g for 3 min. The supernatant was put in a 1.5 ml tube containing 600 µL cold Isopropanol and homogenized gently, then centrifuged at 15000x for 3 min. The supernatant was poured out and 600 µL of 70% ethanol were added to a fresh preparation, which was centrifuged at 15000x g for 3 min. The supernatant was poured out and the tube was completely dried at room temperature. Finally, 100 µL rehydration solution (Wizard® Genomic DNA Purification Kit) was added and the mixture was incubated at 64 °C for 1 h before storing the samples at -20 °C to await further processing.

2.4. DNA evaluation Evaluation of the concentration and purity of DNA was determined by spectrophotometry with an ACT-GENE ASP-3700 spectrometer. The concentration of DNA was evaluated at 260 nm, while purity was estimated with the ratios of 260/203 and 260/280. The integrity of genomic DNA was assessed in a 0.8% agarose gel in 1% TBE (89 mM Tris Borate, 89 mM boric acid, 2 mM EDTA) by electrophoresis, and then the DNA was visualized with Gel-Red and read under UV light. DNA extracted from blood samples was used as the positive control.

2.5. PCR The PCR reaction was carried out in an Eppendorf Mastercycler® Personal apparatus with the HotStarTaq ® Master Mix Qiagen kit (No. de Cat 203445), following the manufacturer's instructions. To verify the quality and species (human) of the DNA extracted, primers were designed for the rs679620 polymorphism (forward 5´- ggg gCT TAA ggC ACA TgA gT-3; reverse 5´- ACT TCg ggA TgC CAg gAA Ag - 3´; Tm: 56°C, 40 cycles) that amplified a product of 485 bp. The final PCR product was evaluated with a 2% agarose gel. DNA extracted from blood samples was used as a positive control.

2.6. Sequencing To further verify the quality and species of the DNA obtained, the product resulting from PCR was sequenced with an Applied Biosystems 3130 sequencer and the BigDye® Terminator v3.1 Cycle Sequencing kit, following the manufacturer's instructions. Data were analyzed with Geneious version 7.1.3 software [23], using the NC_000011.10 sequence as the reference.

Being tested
saliva samples obtained with mouthwash
Keywords
Genomic DNA, chronic periodontitis, saliva, mouthwash, PCR, genotyping, sequencing
Medical subject headings
Chronic Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • saliva samples obtained with mouthwashDevice

    saliva samples obtained with mouthwash

Study groups in NCT02523326
Study groupRoleWhat they receive
Group AEach patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days
Receives: Device: saliva samples obtained with mouthwash
Group BEach patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days
Receives: Device: saliva samples obtained with mouthwash
Group CEach patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days
Receives: Device: saliva samples obtained with mouthwash

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. DNA

    high quality genomic DNA from saliva samples obtained with mouthwash.

    Measured: 10 days [group A], 20 days [group B], 30 days [group C]

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2015 (estimated)
  2. Study startFeb 2015
  3. Primary completionAug 2015
  4. Study completionSep 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02523326
Sponsor's protocol ID
CentroICSUT
Acronym
DPOGDNAS
Status last verified
Aug 2015
First submitted
4 Aug 2015
Last updated
14 Aug 2015
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Periodontal Disease "Unrecognized Condition", run by Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás at 1 site in Mexico.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ángel Chávez Mendoza, PhD student (57296300 ext. 6280, angelchm77@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

DNA (time frame: 10 days [group A], 20 days [group B], 30 days [group C]). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in